See new medication management technology at Omnicell’s innovation lab in South Austin
Omnicell, a technology company specializing in automated medication management systems, has opened a new innovation lab in South Austin. The lab aims to collaborate directly with customers to develop new technologies addressing healthcare challenges such as labor shortages and medication mismanagement. Michael Garel, senior director of innovation, demonstrated various robots and an "XR cabinet" for medication dispensing in a hospital setting.
Omnicell trying to close in on key technical measure
This article states that Omnicell is approaching a key technical measure. Without further content, specific details about this measure or Omnicell's performance cannot be provided. The article suggests an imminent development regarding OMN's stock.
Hospital Robotics (Logistics and Pharmacy) Market to Reach USD 14.77 Billion by 2033 at 13.3% CAGR | North America Holds 40% Share | Key Players: Omnicell, Inc., Aethon Inc., Swisslog Healthcare
The hospital robotics market for logistics and pharmacy is projected to grow from USD 4.8 billion in 2024 to USD 14.77 billion by 2033, exhibiting a CAGR of 13.3%. This growth is primarily driven by increasing hospital workloads, the complexity of medication management, and shortages of skilled healthcare personnel, particularly in North America which holds a 40% market share. Key players in this market include Omnicell, Inc., Aethon Inc., and Swisslog Healthcare, who are expanding the deployment of autonomous mobile robots and advanced pharmacy dispensing systems to enhance efficiency and patient safety.
Does Omnicell’s Profit Squeeze Amid Higher Sales and 2026 Outlook Change The Bull Case For OMCL?
Omnicell, Inc. reported increased revenue for 2025 but a significant decrease in net income, culminating in a quarterly loss for Q4 2025. The company's 2026 revenue guidance highlights ongoing pressure on profitability despite higher sales, raising questions about whether Omnicell can translate demand into consistent, profitable growth. Investors are urged to consider whether cost inflation, buyer consolidation, and commoditization will continue to erode pricing power faster than revenue growth.
Does Omnicell’s Profit Squeeze Amid Higher Sales and 2026 Outlook Change The Bull Case For OMCL?
Omnicell, Inc. recently reported increased full-year 2025 revenue but a significant drop in net income, including a net loss in Q4 2025. This profitability squeeze, despite higher sales and moderate 2026 revenue guidance, complicates the bull case for OMCL, which relies on consistent, profitable growth from demand for automation and medication management. The article suggests that while revenue is growing, pressure from input costs, tariffs, and competitive pricing continues to challenge Omnicell's margins and overall profitability.
A Look At Omnicell (OMCL) Valuation After Earnings Reveal Cost Pressures On Profitability
Omnicell (OMCL) recently reported earnings where revenue met expectations, but non-GAAP profitability was lower due to increased spending on new products and customer experience. Despite a narrative suggesting a fair value of $51.50, based on a shift to recurring SaaS-based revenues, the share price has seen significant declines over varying periods. The article prompts investors to consider whether the stock is undervalued or if market prices already reflect its future growth, while also highlighting risks like tariff costs and potential slowdowns in hospital capital spending.
Reassessing Omnicell (OMCL) After Sharp Multi‑Year Share Price Declines
This article reassesses Omnicell (OMCL) after significant share price declines, noting a 72.1% drop over five years. Using a Discounted Cash Flow (DCF) analysis, the stock appears undervalued by 23.4% with an intrinsic value of $47.25 per share against a current price of $36.18. However, a Price-to-Sales (P/S) comparison suggests it is overvalued when measured against Simply Wall St's proprietary Fair Ratio of 1.07x, as its current P/S is 1.37x.
Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues As Shares Take 26% Pounding
Omnicell, Inc. (NASDAQ:OMCL) shares have dropped 26% recently, contributing to a 6.6% annual decline. The company's low price-to-sales (P/S) ratio of 1.4x, compared to an industry average above 2.9x, is attributed to sluggish revenue growth, with an 8.6% drop over the last three years and a projected annual growth of only 4.8% by analysts, significantly trailing the industry's 124% forecast. This outlook suggests limited future growth potential, leading to shareholder disinterest and a reduced stock valuation.
The Top 5 Analyst Questions From Omnicell's Q4 Earnings Call
Omnicell's Q4 earnings call saw revenue in line with expectations but a significant shortfall in non-GAAP profitability, attributed to product mix shifts and higher operating costs. Analysts focused on the Titan XT refresh cycle, competitive dynamics, leverage of AI tools, and the performance of various business segments. The company's future catalysts include the Titan XT and Omnisphere demand, cost management, and growth in annual recurring revenue.
The Top 5 Analyst Questions From Omnicell’s Q4 Earnings Call
Omnicell's Q4 earnings call revealed a negative market reaction due to a notable shortfall in non-GAAP profitability despite in-line revenue. The company attributed this to product and customer mix shifts, as well as higher operating costs related to new product introductions and customer experience initiatives. Analysts focused on the Titan XT refresh cycle, competitive dynamics, leverage, and the performance of various business segments.
Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge
Omnicell, Inc. (NASDAQ:OMCL) has seen its share price drop by 26% in the last 30 days, primarily due to sluggish revenue growth which has resulted in a low price-to-sales (P/S) ratio compared to the Medical Equipment industry. Analysts project Omnicell's revenue to grow by only 4.8% annually over the next three years, significantly underperforming the industry's predicted 124% growth, thus justifying the reduced stock valuation. This underperformance in revenue growth is cited as the main reason for the depressed P/S ratio and the stock's recent decline.
Omnicell (NASDAQ:OMCL) Cut to Strong Sell at Zacks Research
Zacks Research downgraded Omnicell (NASDAQ:OMCL) to a "strong sell" rating after the company missed EPS estimates and showed only 2.3% year-over-year revenue growth. Despite the downgrade, analysts' overall coverage remains mixed with an average price target of $54.29, though the stock trades around $39 with a high P/E ratio. Insiders have recently sold shares, while institutional investors hold a significant portion of the company's stock.
Omnicell, Inc. (OMCL) Stock Analysis: Unpacking a Potential 57% Upside in Healthcare Automation
This article analyzes Omnicell, Inc. (OMCL), a healthcare automation company specializing in medication management. Analysts project a potential upside of 57.34% for OMCL, driven by its strategic outlook, innovative product offerings, and strong market position. The company's financial health indicators, such as a steady revenue growth and positive free cash flow, along with a low Relative Strength Index suggesting an oversold condition, make it an intriguing option for investors focusing on long-term growth in the healthcare sector.
Omnicell (OMCL) Margin Squeeze To 0.2% Net Profit Tests Bullish Recovery Narratives
Omnicell (OMCL) reported a net profit margin of 0.2% for the trailing 12 months of FY 2025, down from 1.1% the previous year, with quarterly EPS exhibiting significant volatility. A non-recurring US$4.6 million loss contributed to the slim profit, complicating the bearish narrative of declining earnings over five years. Despite being discounted compared to industry multiples, bulls see potential upside due to a DCF fair value above the current share price and an 86% annual earnings growth forecast over the next three years, though revenue growth remains modest.
Omnicell (NASDAQ:OMCL) Downgraded to "Hold" Rating by Wall Street Zen
Wall Street Zen has downgraded Omnicell (NASDAQ:OMCL) from a "buy" to a "hold" rating, contributing to a consensus "Moderate Buy" rating with an average target price of $54.29 among analysts. This downgrade follows Omnicell's Q4 EPS miss, reporting $0.40 against an estimated $0.47, despite revenue being largely in line at $314 million. The company's shares dropped by approximately 5.1% due to the EPS miss and noted margin pressures.
Analysts Conflicted on These Healthcare Names: Cigna (CI), Hims & Hers Health (HIMS) and Omnicell (OMCL)
The article summarizes recent analyst ratings for Cigna (CI), Hims & Hers Health (HIMS), and Omnicell (OMCL). Bank of America Securities reiterated a Buy on Cigna, while also issuing a Sell rating for Hims & Hers Health. Wells Fargo maintained a Buy rating on Omnicell, which also received an upgrade to Buy from TipRanks – OpenAI.
Omnicell (OMCL) Margin Squeeze To 0.2% Net Profit Tests Bullish Recovery Narratives
Omnicell (OMCL) concluded FY 2025 with Q4 revenue of US$314 million and a basic EPS loss of US$0.05, resulting in a slim trailing twelve-month net profit margin of 0.2%. This tight margin and earnings volatility, including a US$4.6 million non-recurring loss, challenge optimistic recovery narratives despite the company's valuation discounts and expected earnings growth. The market appears to be weighing current profitability issues more heavily than future growth forecasts.
Omnicell, Inc. (NASDAQ:OMCL) Q4 2025 Earnings Call Transcript
Omnicell, Inc. (NASDAQ:OMCL) reported its Q4 2025 earnings, missing EPS expectations at $-0.04506 against an anticipated $0.47, yet achieved revenues, bookings, and Annual Recurring Revenue (ARR) above the midpoint of guidance. The company highlighted strong performance in its Point of Care business, increasing demand for its XT S10 devices, and introduced its new enterprise-wide automation dispensing system, Titan XT, designed to unify automation and intelligence on the Omnisphere cloud-based platform. Omnicell reaffirmed its commitment to expanding market presence, scaling recurring revenue, and accelerating its technology platform, Omnisphere, to drive long-term value and position itself for sustainable profitable growth in 2026 and beyond.
Omnicell Q4 2025 Earnings: Stock Dives on Missed EPS, 2026 Guidance - News and Statistics
Omnicell's shares dropped 18.4% after the company reported fourth-quarter 2025 adjusted earnings of $0.40 per share, missing analyst estimates of $0.50. While revenue met expectations, the significant profit miss and a disappointing 2026 financial year forecast, including adjusted EPS and EBITDA below analyst expectations, fueled investor concern. This decline continues a volatile period for Omnicell, with its stock down 11% year-to-date and 21.8% below its 52-week high.
Omnicell Stock Pre-Market (-15%) : Q4 EPS Miss & Weak 2026 Guidance
Omnicell (OMCL) stock is down 15% pre-market due to a significant Q4 profit miss and a disappointing 2026 forecast, despite a minor revenue beat. The company's adjusted EPS missed estimates by 20%, and non-GAAP EBITDA fell 21% year-over-year, indicating severe margin pressure. Analysts suggest that if OMCL fails to hold the $38.00 pivot point, further downside is likely.
Omnicell (OMCL) Valuation Check After Earnings Miss And Cautious 2026 Outlook
Omnicell (OMCL) recently reported Q4 and full-year 2025 results, showing a net loss and adjusted earnings below analyst expectations, coupled with cautious 2026 guidance. This led to a significant share price decline, although the company is still considered 24.1% undervalued by Simply Wall St based on future cash flows, trading at US$39 against a fair value of US$51.50. However, its current P/E ratio of 88x is substantially higher than the industry average, posing a risk if growth or margins underperform.
Why Omnicell (OMCL) Shares Are Plunging Today
Omnicell (OMCL) shares plunged by over 18% after the company reported fourth-quarter earnings below Wall Street expectations and issued a disappointing forecast for the 2026 financial year. Despite meeting revenue estimates, adjusted earnings per share missed analyst predictions, and the company's full-year guidance signaled potential weakness, contributing to investor concerns.
Omnicell: Fourth Quarter Financial Highlights
Omnicell Inc. reported a net loss of $2 million, or 5 cents per share, for the fourth quarter, with adjusted earnings of 40 cents per share falling short of analysts' expectations of 47 cents. Despite the earnings miss, the company surpassed revenue forecasts with $314 million. For the full year, Omnicell posted a profit of $2.1 million on $1.18 billion in revenue and provided an outlook for Q1 and full-year earnings and revenue.
Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results
Omnicell, a healthcare technology provider, has released its financial results for Q4 and the full fiscal year 2025, showing increased revenues but a GAAP net loss for the quarter. The company launched its new dispensing system, Titan XT, and projects continued revenue growth for fiscal year 2026.
Omnicell: Fourth Quarter Financial Highlights
Omnicell Inc. reported a net loss of $2 million and a loss of 5 cents per share for the fourth quarter, with adjusted earnings of 40 cents per share missing analyst expectations. Despite this, the company surpassed revenue forecasts, generating $314 million. For the full year, Omnicell posted a profit of $2.1 million on revenues of $1.18 billion and provided an outlook for the upcoming quarter and full year.
Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results
Omnicell (NASDAQ:OMCL) announced solid fiscal year and fourth quarter 2025 financial results, with total revenues for Q4 2025 reaching $314 million, a 2% increase from Q4 2024. For the full year 2025, total revenues were $1.185 billion, up 7% from 2024. The company also launched its next-generation dispensing system, Titan XT, aiming to enhance autonomous medication management and provide 2026 guidance including projected revenues between $1.215 billion and $1.255 billion.
OMNICELL ($OMCL) Releases Q4 2025 Earnings
OMNICELL ($OMCL) reported its Q4 2025 earnings, missing analyst estimates for both earnings per share and revenue. The company reported earnings of $0.40 per share against an estimated $0.51, and revenue of $313.98 million against an estimated $319.66 million. The article also provides details on insider trading activity, institutional holdings changes, government contracts awarded, and recent analyst ratings and price targets for OMCL.
Omnicell stock upgraded at Bank of America (OMCL:NASDAQ)
Bank of America upgraded Omnicell (OMCL) from Neutral to Buy, increasing its price target to $70 from $53 per share. This upgrade is based on a perceived buying opportunity for the pharmacy automation solutions provider, ahead of its upcoming Q4 2025 results.
Omnicell stock rating upgraded by BofA Securities on Titan XT launch potential
BofA Securities upgraded Omnicell (NASDAQ:OMCL) from Neutral to Buy, increasing its price target to $70.00, citing significant upside potential from the upcoming launch of its Titan XT product. The upgrade aligns with InvestingPro’s Fair Value assessment, which indicates the stock is undervalued. This positive outlook is supported by Omnicell's strong historical performance and its industry leadership in automated dispensing cabinets.
Understanding the Setup: (OMCL) and Scalable Risk
The article analyzes Omnicell Inc. (NASDAQ: OMCL), noting weak near and mid-term sentiment but a strong long-term outlook. It identifies that resistance is being tested and highlights an exceptional 54.0:1 risk-reward short setup. Three distinct AI-generated trading strategies are provided: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, along with multi-timeframe signal analysis.
Omnicell Earnings: What To Look For From OMCL
Omnicell (NASDAQ:OMCL) is set to announce its earnings results this Thursday before market hours. Analysts predict a 2.4% year-on-year revenue growth to $314.2 million and adjusted earnings of $0.50 per share. The company has a history of surpassing Wall Street's revenue expectations, beating estimates by an average of 3.8% over the past two years.
Is Omnicell (OMCL) Starting To Look Interesting After Recent Share Price Swings?
Omnicell (OMCL) has experienced recent stock price fluctuations, with an 11.2% undervaluation according to a Discounted Cash Flow (DCF) analysis, suggesting it could be a bargain at its current US$46 share price. However, its Price/Earnings ratio of 103.7x is significantly higher than the Medical Equipment industry average, leading to an "overvalued" assessment by Simply Wall St's proprietary "Fair Ratio." The article encourages investors to use "Narratives" on Simply Wall St to integrate their own market views with financial forecasts for a more personalized valuation.
Omnicell, Inc. (OMCL) Stock Analysis: Investor Optimism Soars with 15.87% Potential Upside
Omnicell, Inc. (NASDAQ: OMCL) is attracting investor attention within the healthcare information services sector, driven by strong analyst sentiment and a potential upside of 15.87%. The company demonstrates robust revenue growth, positive free cash flow, and strategic market positioning with its medication management solutions. Despite some volatility, technical indicators suggest a potential entry point for investors interested in healthcare technology.
Omnicell stock price target raised to $60 from $50 at Benchmark
Benchmark has raised its price target for Omnicell (NASDAQ:OMCL) to $60 from $50, maintaining a Buy rating on the healthcare technology company due to strong financial health and positive momentum. This increase comes ahead of Omnicell's 2026 results, driven by successful product revenue guidance increases related to new dispensing cabinet upgrades. Other analysts like KeyBanc Capital Markets and BofA Securities also hold positive outlooks on Omnicell, with increased price targets and upgraded ratings.
Omnicell stock price target raised to $60 from $50 at Benchmark
Benchmark raised its price target for Omnicell (NASDAQ:OMCL) to $60 from $50, maintaining a Buy rating, ahead of the company's 2026 results. The increase is driven by strong stock performance over the last three and six months, attributed to positive product revenue guidance from new dispensing cabinet upgrades and expanded salesforce productivity. Analysts anticipate Omnicell will guide FY26 above consensus models, and the stock a perfect Piotroski Score of 9.
Omnicell, Inc. (NASDAQ:OMCL) Receives Average Recommendation of "Hold" from Analysts
Omnicell, Inc. (NASDAQ:OMCL) has an average "Hold" rating from eight analysts, with a 12-month target price around $48.57. Recent analyst upgrades from "sector weight" or "sell" to "overweight" or "hold" were noted, alongside a price target increase from Wells Fargo. Insider selling by EVP Corey J. Manley accounted for a 6.24% reduction in his position, while institutional investors significantly increased their holdings, owning 97.7% of the company's stock.
Healthcare Technology for Providers Stocks Q3 Highlights: Omnicell (NASDAQ:OMCL)
This article reviews the Q3 earnings for healthcare technology providers, focusing on Omnicell (NASDAQ:OMCL), Privia Health (NASDAQ:PRVA), Astrana Health (NASDAQ:ASTH), and Evolent Health (NYSE:EVH). While the sector generally met revenue expectations, share prices struggled post-earnings. Omnicell reported strong financial performance with revenues up 10% year-on-year, impressing analysts, while Privia Health also exceeded expectations significantly, despite its stock decline. Astrana Health and Evolent Health experienced weaker quarters, with significant misses on EPS estimates and substantial stock drops.
Federated Hermes Inc. Cuts Stake in Omnicell, Inc. $OMCL
Federated Hermes Inc. significantly reduced its stake in Omnicell, Inc. by 11.7% in Q3, selling 69,505 shares and now holding 525,439 shares valued at approximately $16 million. In related news, Omnicell EVP Corey J. Manley also decreased his holdings by 6.24% through a sale in January. Analysts maintain a "Hold" consensus rating for OMCL, with an average price target of $48.57.
Omnicell Stock In Focus: Quiet Chart, Cautious Street, And A Healthcare Tech Wild Card
Omnicell (OMCL) stock is currently in a low-key consolidation phase, trading closer to its 52-week lows, as Wall Street analysts adopt a cautious stance. Despite healthy one-year returns, the market is awaiting cleaner execution of its cloud-driven, subscription-based offerings and consistent growth before pushing the stock higher. Future catalysts include recurring revenue growth, improved margins, and significant contract wins that will determine if the stock breaks out of its current holding pattern.
Omnicell (OMCL) Expected to Announce Earnings on Thursday
Omnicell (NASDAQ: OMCL) is scheduled to announce its Q4 2025 earnings before market open on Thursday, February 5th, with analysts forecasting earnings of $0.47 per share. The stock opened at $49.04, with a market cap of $2.20 billion and a P/E ratio of 114.05, despite a "Hold" consensus rating and an average price target of $48.57 from analysts. Insider selling by EVP Corey J. Manley was reported, while institutional investors hold approximately 97.7% of the company's stock.
Earnings Preview: Omnicell (OMCL) Q4 Earnings Expected to Decline
Omnicell (OMCL) is expected to report a year-over-year decline in Q4 earnings, despite projected higher revenues, when it releases its results around February 5th. Analysts have revised the consensus EPS estimate lower, and the company's Earnings ESP suggests analysts are bearish, making it difficult to predict an earnings beat despite a favorable Zacks Rank. Investors are advised to consider other factors beyond just an earnings beat or miss.
Omnicell XT Amplify Launch Highlights Digital Health Role And Rich Valuation
Omnicell (OMCL) has expanded its digital healthcare offerings with the launch of its XT Amplify program, focusing on medication management solutions for hospitals. While the stock has seen recent positive momentum, its current P/E ratio of 113.3 is significantly higher than the industry average, indicating a rich valuation. The success of these new offerings will depend on their adoption by health systems aiming to improve safety and efficiency.
Omnicell XT Amplify Launch Highlights Digital Health Role And Rich Valuation
Omnicell (NasdaqGS:OMCL) has launched its XT Amplify program, expanding its focus on digital healthcare solutions for medication management in hospitals. While the stock has seen recent positive momentum, its current P/E ratio is significantly higher than the industry average, underscoring the importance of successful execution of these new offerings. Investors should monitor the adoption of these solutions and recurring software revenue to assess Omnicell's future role in healthcare workflows.
Omnicell XT Amplify Puts Medication Management And Growth Story To Test
Omnicell (NasdaqGS:OMCL) has launched its XT Amplify program, focusing on expanding its automated medication management offerings to meet the growing demand for digital healthcare tools. While the company has seen recent share price strength, its long-term financial performance presents a mixed picture. The success of XT Amplify will be a crucial test of Omnicell's ability to shift its narrative towards consistent growth driven by software-rich solutions rather than relying on equipment sales.
Omnicell (NASDAQ:OMCL) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened
Omnicell (NASDAQ:OMCL) shares recently crossed above their 200-day moving average, trading as high as $51.14 and closing at $50.30. Several analysts have upgraded the stock and raised price targets, though the MarketBeat consensus remains a "Hold" with an average price target of $48.57. Despite an elevated PE ratio of 116.98, institutional investors hold a significant 97.7% stake in the company.
Omnicell XT Amplify Puts Medication Management And Growth Story To Test
Omnicell has launched its XT Amplify program, focusing on expanding its automated medication management offerings, aligning with the growing demand for digital healthcare tools. While the company's recent share price performance has been positive, its long-term growth and declining EPS suggest past challenges. The success of XT Amplify will be crucial in proving Omnicell's ability to drive consistent growth through software-rich solutions rather than relying solely on hardware sales.
Operating Room Management Market Innovations and Key Players:
The Operating Room Management market is undergoing significant transformation due to technological advancements and a focus on surgical suite optimization. Key drivers include sustainability, digitization, AI, and machine learning, which are enhancing efficiency, patient safety, and workflow management. The market is segmented by type (services, software) and application (anesthesia, data, supply, scheduling, performance management), with major players like Cerner Corp., McKesson Corp., and GE Healthcare driving innovation.
3 Reasons to Sell OMCL and 1 Stock to Buy Instead
Omnicell (OMCL) has seen its stock price jump 80.2% in the past six months, but a deeper analysis suggests it may underperform. The company exhibits disappointing long-term revenue growth, shrinking adjusted operating margins, and declining EPS. Based on these factors, the article recommends selling OMCL and suggests other high-quality stocks for investment.
Omnicell stock price target raised to $53 from $46 at BofA Securities
BofA Securities has increased its price target for Omnicell (NASDAQ:OMCL) to $53 from $46, while maintaining a Neutral rating. This adjustment follows incrementally positive results from BofA's capital expenditure survey, indicating improved pharmacy IT budget growth expectations and a more constructive market backdrop supporting Omnicell's new product cycle. The company has shown strong revenue growth and impressive price performance, with analysts expressing growing confidence in its future prospects following recent product launches.
Sumitomo Mitsui Trust Group Inc. Sells 25,054 Shares of Omnicell, Inc. $OMCL
Sumitomo Mitsui Trust Group Inc. reduced its stake in Omnicell, Inc. by 1.8%, selling 25,054 shares and now holding 1,398,550 shares valued at approximately $42.6 million. This transaction comes amidst mixed Wall Street sentiment, with a consensus "Hold" rating but some analysts upgrading and setting higher price targets. An Omnicell EVP also sold 6,106 shares, reducing their ownership by 6.24%.
